This study investigates treatments for hormone-sensitive prostate cancer that has spread to other parts of the body. The purpose is to see if adding cabazitaxel to abiraterone acetate and antiandrogen therapy can improve progression-free survival in patients who have already been treated with docetaxel and androgen deprivation therapy. Hormone-sensitive prostate cancer means the cancer responds to treatments that lower testosterone.
Participants will receive either abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone. Cabazitaxel is a chemotherapy drug, and prednisone is a steroid that can help manage side effects. The study aims to compare the effectiveness of these treatments in controlling cancer progression.
- Who can participate: Men with a confirmed diagnosis of prostate cancer who have previously undergone at least 3 cycles of docetaxel chemotherapy for metastatic hormone-sensitive prostate cancer are eligible.
- Study details: Participants will be assigned to receive either abiraterone acetate and antiandrogen therapy alone or with additional cabazitaxel and prednisone. A placebo is not used in this study.
